# Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

> **NCT00396006** · PHASE4 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 21 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **BIOLOGICAL:** Alpha1-Proteinase Inhibitor

## Key facts

- **NCT ID:** NCT00396006
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-27
- **Primary completion:** 2007-12-14
- **Final completion:** 2007-12-14
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396006, "Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00396006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*